CSIMarket Company Name, Ticker, Competitors, else..
 
Cingulate Inc   (NASDAQ: CING)
 
Price: $5.0900 $-0.02 -0.391%
Day's High: $5.209700107574463 Week Perf: -1.55 %
Day's Low: $ 5.09 30 Day Perf: -2.3 %
Volume (M): 76,731 52 Wk High: $ 11.89
Volume (M$): $ 0 52 Wk Avg: $5.02
Open: $5.16 52 Wk Low: $3.16



 Market Capitalization (Millions $) 67
 Shares Outstanding (Millions) 13
 Employees 14
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -29
 Cash Flow (TTM) (Millions $) 17
 Capital Exp. (TTM) (Millions $) 0

Business Description


Cingulate Inc is a neurotechnology company that focuses on developing innovative solutions aimed at improving brain health and performance. The company uses advanced technologies to create non-invasive, personalized, and scalable tools that can be utilized in various industries, including healthcare, sports, and education. Cingulate Inc specializes in the development of brain computer interface (BCI) systems, wearable devices, and software applications that can assess brain activity, provide neurofeedback, and enhance cognitive functions. Their products and services are designed to help individuals optimize their brain states, enhance mental well-being, and achieve peak performance.


   Company Address: 1901 W. 47th Place Kansas City 66205 KS
   Company Phone Number: 942-2300   Stock Exchange / Ticker: NASDAQ CING


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
DMAC        0.61% 
IRWD        2.46% 
NRXP   -0.59%    
PHAT   -11.3%    
RLMD        3.18% 
SUPN   -1.64%    
• View Complete Report
   



Management Announcement

Cingulate Inc. Seizes Growth Momentum: CEO Shane Schaffer Discusses ADHD Innovations Amid Financial Transformation on Big Biz Show,

Published Tue, Oct 8 2024 7:15 PM UTC

In a significant development for Cingulate Inc. (NASDAQ: CING), a Kansas City-based biopharmaceutical company specialized in innovative drug delivery platforms, Shane J. Schaffer, Chairman and CEO, recently participated in the nationally syndicated Big Biz Show. During this broadcast, Schaffer provided insights into the company s leading asset, CTx-1301, which is currently u...
Financing Agreement

Cingulate's Strategic Move Signals Robust Growth Potential

Published Fri, Jun 28 2024 1:15 PM UTC


In a significant development, Cingulate Inc., a Kansas City-based biopharmaceutical company, has recently announced the immediate exercise of a substantial number of Series A and Series B warrants, leading to gross proceeds of $1.86 million. This move showcases the company s commitment to advancing its pipeline of next-generation pharmaceutical products, leveraging its ...
Stock Market Announcement

Cingulate Inc. Successfully Closes Public Offering, Demonstrating Strong Investor Confidence Amidst Promising Pipeline of Pharmaceutical Products

Published Tue, Feb 6 2024 9:15 PM UTC



KANSAS CITY, Kan., Feb. 06, 2024 - Biopharmaceutical company Cingulate Inc. (NASDAQ: CING) recently announced the successful completion of its public offering, marking a significant milestone in the advancement of its pipeline of next-generation pharmaceutical products. With its proprietary Precision Timed Release (PTR) drug delivery platform technology, Cingulate ...
Financing Agreement

Werth Family Investment Associates Converts Remaining $33M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Published Mon, Jan 29 2024 11:45 AM UTC

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
Kansas City, Kan. - Biopharmaceutical company Cingulate Inc. (NASDAQ: CING) has recently made an exciting announcement regarding its latest financial developments. Werth Family Investment Associates, LLC (WFIA), the manager of which is Peter...
Product Service News

Cingulate's Precision Timed Release Therapy for Anxiety Receives FDA Guidance, Shaping a New Era in Treatment

Published Fri, Dec 1 2023 2:00 PM UTC


Introduction
Cingulate Inc., a biopharmaceutical company focused on developing next-generation pharmaceutical products, has announced receiving guidance from the Food and Drug Administration (FDA) on moving forward with its investigational asset CTx-2103 (buspirone) to combat anxiety. This development is a significant step in addressing the growing prevalence of anx...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 2.86
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.29
Working Capital Ratio 3.51
Leverage Ratio (MRQ) 0.41
Total Debt to Equity 0.22
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.99 $
Revenues (TTM) -
Cash Flow (TTM) 1.29 $
Cash 2.15 $
Book Value 1.78 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,074,346
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.